Nuvigil Gets Protection Until 2023 Under New Patent
This article was originally published in The Pink Sheet Daily
Executive Summary
Composition-of-matter claim for “enantiomers of modafinil” adds a decade to the patent life of Cephalon’s follow-on wakefulness treatment.
You may also be interested in...
FDA Approves Cephalon’s Nuvigil With Bolded Warning For Rash
Company tells “The Pink Sheet” DAILY it is set to begin studies in other therapeutic areas to boost labeling before commercial launch.
FDA Approves Cephalon’s Nuvigil With Bolded Warning For Rash
Company tells “The Pink Sheet” DAILY it is set to begin studies in other therapeutic areas to boost labeling before commercial launch.
Provigil Will Remain Cephalon’s Marketing Focus As Partner Takeda Adds Reps
Nuvigil will be a “modest” launch in 2007 as Cephalon looks to expand labeling ahead of enhanced marketing in 2010.